Total Number of Shares and Voting Rights in Zealand Pharma
Recently, Zealand Pharma A/S, a biotechnology firm dedicated to developing peptide-based medicines, made a significant announcement regarding its share capital. This report provides an overview of the total number of shares and voting rights at the close of the reporting period, underscoring the company's commitment to transparency.
Significant Changes in Share Capital
On the 30th of a recent month, Zealand Pharma revealed an increase in its share capital resulting from the exercise of employee warrants. This change follows an earlier announcement that emphasized the company's proactive strategy for engaging stakeholders and encouraging employee involvement in its growth.
Details of Shares and Voting Rights
The latest report indicates that the total number of shares outstanding has reached 71,013,761, which corresponds to a total share capital of the same nominal value in DKK. This number reflects a strong foundation for the company as it navigates the dynamic biotechnology and medical landscape.
About Zealand Pharma
Established in 1998 and based in Copenhagen, Zealand Pharma (NASDAQ: ZEAL) is focused on developing innovative peptide-based treatments. With over ten drug candidates currently in clinical development—two of which have received market approval—the company demonstrates resilience and ambition within the pharmaceutical sector. Zealand has also formed strategic partnerships with prominent pharmaceutical companies, bolstering its market presence and product offerings.
Progress in Drug Development
Zealand Pharma's success in drug discovery highlights its innovative approach. The company has advanced multiple candidates through various stages of clinical trials, with three potential products currently in late-stage development. This progress showcases the effectiveness of Zealand's research efforts and its ongoing commitment to enhancing patient outcomes through advanced therapeutics.
Contact Information for Inquiries
If you're interested in learning more about Zealand Pharma's operations, please reach out to the following contacts:
Adam Lange
Investor Relations Officer
Email: akl@zealandpharma.com
Anna Krassowska, PhD
Vice President, Investor Relations & Corporate Communications
Email: ank@zealandpharma.com
Frequently Asked Questions
1. What is the total number of shares for Zealand Pharma as of the latest announcement?
The total number of shares for Zealand Pharma is 71,013,761.
2. What does the increase in share capital signify?
The increase in share capital indicates growth and positive developments as a result of employee warrants being exercised.
3. How does Zealand Pharma engage with its employees?
Zealand Pharma engages with employees through initiatives like employee warrants, encouraging them to participate in the company's growth.
4. Where is Zealand Pharma headquartered?
Zealand Pharma is headquartered in Copenhagen, Denmark.
5. What type of medicines does Zealand Pharma focus on?
Zealand Pharma focuses on the discovery and development of innovative peptide-based medicines.